Individual time course of pre- and postsynaptic PET imaging may improve differential diagnosis of Parkinson’s disease and multiple system atrophy: a case report

The most common disorder in a patient presenting to a movement disorder clinic will be parkinsonism. The challenge is to provide the patient with the most accurate diagnosis and prognosis possible. The assumption at the time of initial presentation of the clinical diagnosis of Parkinson's disease is often wrong (20-25%). Waiting to see the pattern of progression, and response to medication provides invaluable additional information. This manuscript summarizes the clinical manifestations of Parkinson's disease and the main akinetic-rigid syndromes (progressive supranuclear palsy, multiple system atrophy, cortical-basal ganglionic degeneration, and dementia with Lewy bodies) that make up the differential diagnosis.

Download Full-text

Neuroimaging in Parkinsonism: a study with magnetic resonance and spectroscopy as tools in the differential diagnosis

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2009000100002 ◽

2009 ◽

Vol 67 (1) ◽

pp. 1-6 ◽

Cited By ~ 6

Author(s):

Luiz Felipe Rocha Vasconcellos ◽

Sergio A. Pereira Novis ◽

Denise Madeira Moreira ◽

Ana Lucia Z. Rosso ◽

Ana Claudia C.B. Leite

Keyword(s):

Magnetic Resonance Imaging ◽

Parkinson’S Disease ◽

Parkinson's Disease ◽

Differential Diagnosis ◽

Magnetic Resonance ◽

Multiple System Atrophy ◽

Rating Scale ◽

Resonance Spectroscopy ◽

Resonance Imaging ◽

Imaging And Spectroscopy

The differential diagnosis of Parkinsonism based on clinical features, sometimes may be difficult. Diagnostic tests in these cases might be useful, especially magnetic resonance imaging, a noninvasive exam, not as expensive as positron emission tomography, and provides a good basis for anatomical analysis. The magnetic resonance spectroscopy analyzes cerebral metabolism, yielding inconsistent results in parkinsonian disorders. We selected 40 individuals for magnetic resonance imaging and spectroscopy analysis, 12 with Parkinson's disease, 11 with progressive supranuclear palsy, 7 with multiple system atrophy (parkinsonian type), and 10 individuals without any psychiatric or neurological disorders (controls). Clinical scales included Hoenh and Yahr, unified Parkinson's disease rating scale and mini mental status examination. The results showed that patients with Parkinson's disease and controls presented the same aspects on neuroimaging, with few or absence of abnormalities, and supranuclear progressive palsy and multiple system atrophy showed abnormalities, some of which statistically significant. Thus, magnetic resonance imaging and spectroscopy could be useful as a tool in differential diagnosis of Parkinsonism.

Download Full-text

Comparison of brain MRI and 18F-FDG PET in the differential diagnosis of multiple system atrophy from Parkinson's disease

Movement Disorders ◽

10.1002/mds.21714 ◽

2007 ◽

Vol 22 (16) ◽

pp. 2352-2358 ◽

Cited By ~ 26

Author(s):

Kyum-Yil Kwon ◽

Choong G. Choi ◽

Jae S. Kim ◽

Myoung C. Lee ◽

Sun J. Chung

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Differential Diagnosis ◽

Multiple System Atrophy ◽

Fdg Pet ◽

Brain Mri ◽

18F Fdg

Download Full-text

Serum miR-96-5P and miR-339-5P Are Potential Biomarkers for Multiple System Atrophy and Parkinson's Disease

Frontiers in Aging Neuroscience ◽

10.3389/fnagi.2021.632891 ◽

2021 ◽

Vol 13 ◽

Author(s):

Annamaria Vallelunga ◽

Tommaso Iannitti ◽

Sabrina Capece ◽

Gerardina Somma ◽

Maria Claudia Russillo ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Differential Diagnosis ◽

Multiple System Atrophy ◽

Neurodegenerative Diseases ◽

Target Genes ◽

Fold Change ◽

Serum Samples ◽

Non Invasive ◽

Novel Biomarkers

Parkinson's disease (PD) and Multiple System Atrophy (MSA) are progressive neurodegenerative diseases with overlap of symptoms in early stages of disease. No reliable biomarker exists and the diagnosis is mainly based on clinical features. Several studies suggest that miRNAs are involved in PD and MSA pathogenesis. Our goal was to study two serum circulating microRNAs (miR-96-5p and miR-339-5p) as novel biomarkers for the differential diagnosis between PD and MSA. Serum samples were obtained from 51 PD patients, 52 MSA patients and 56 healthy controls (HC). We measured levels of miRNAs using quantitative PCR and compared the levels of miR-96-5p and miR-339-5p among PD, MSA and HC groups using a one-way analysis of variance. Correlations between miRNA expression and clinical data were calculated using Pearson's rho test. We used the miRTarBase to detect miRNA targets and STRING to evaluate co-expression relationship among target genes. MiR-96-5p was significantly increased in MSA patients compared with HC (Fold change (fc): 3.6; p = 0.0001) while it was decreased in PD patients compared with HC (Fold change: 4; p = 0.0002). Higher miR-96-5P levels were directly related to longer disease duration in MSA patients. We observed a significant increase of miR-339-5p in MSA patients compared with PD patients (fc: 2.5; p = 0.00013). miR-339-5p was increased in MSA patients compared with HC (fc: 2.4; p = 0.002). We identified 32 target genes of miR-96-5p and miR-339-5p, some of which are involved in neurodegenerative diseases. The study of those miRNAs could be useful to identify non-invasive biomarkers for early differential diagnosis between PD and MSA.

Download Full-text